Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXT03
- Development stage
- Preclinical
- Lead developer
- DanCann Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Sublingual
01
Overview
EXT03 (CannGros) is a standardized botanical extract developed by DanCann Pharma for medicinal use. It is formulated to replicate the cannabinoid profile of the Bediol strain, which features a balanced ratio of approximately 6.3% delta-9-tetrahydrocannabinol (THC) and 8% cannabidiol (CBD). The extract is intended for the treatment of conditions where medicinal cannabis is indicated, such as chronic pain, spasticity associated with multiple sclerosis, and chemotherapy-induced nausea and vomiting. As a botanical extract, it utilizes the synergistic effects of multiple cannabinoids and terpenes, often referred to as the entourage effect, to provide therapeutic benefits while potentially mitigating the psychoactive side effects of high-THC formulations.
- Brand names
- CannGros
- Other names
- Bediol formulationBediol Extract formulation
02
Targets
CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on EXT03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXT03.